You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, August 2019
|
| DOI | 10.1186/s13195-019-0520-1 |
| Pubmed ID | |
| Authors |
Michael F. Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie Stone, Christine Furtek, Erin Mahoney, Jeffrey L. Cummings, Pierre N. Tariot, Paul S. Aisen, Bruno Vellas, Christopher Lines, David Michelson |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 128 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 19 | 15% |
| Student > Master | 14 | 11% |
| Student > Ph. D. Student | 11 | 9% |
| Researcher | 9 | 7% |
| Other | 6 | 5% |
| Other | 18 | 14% |
| Unknown | 51 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 14% |
| Neuroscience | 17 | 13% |
| Biochemistry, Genetics and Molecular Biology | 8 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Nursing and Health Professions | 4 | 3% |
| Other | 19 | 15% |
| Unknown | 57 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2019.
All research outputs
#2,998,334
of 23,153,849 outputs
Outputs from Alzheimer's Research & Therapy
#738
of 1,253 outputs
Outputs of similar age
#63,482
of 345,119 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#17
of 27 outputs
Altmetric has tracked 23,153,849 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,253 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.9. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,119 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.